Next Generation Drug Response Profiling for Personalized Cancer Care
Despite rapid progress in cancer genomics and molecular disease classification, it remains difficult to identify actionable targets and predict response to drugs based on this information. New approaches that identify cancer vulnerabilities and predict the response to treatment based on pre-treatment testing of individual cancer cells could improve response rates, reduce unnecessary treatments, and significantly increase cost-effectiveness. Based on strong proof-of-concept data, the CRPP hypothesizes that critical predictive and mechanistic information can be obtained from direct functional drug response screening of primary patient samples. The CRPP joins forces to develop a clinical platform for next-generation precision medicine at UZH, to apply drug response profiling to personalize treatment of patients and investigate unexpected vulnerabilities at depth.